Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nevro reports strong Q4 earnings, eyes market growth opportunities

Nevro's Q4 2022 performance reflects revenue growth, strong trial rates, and market share gains, with expectations for continued growth.
Challenges include pandemic impact, pricing pressure, and questions on clinical benefits quantification and CEO search progress.
Opportunities lie in market share gains, differentiation through HFX iQ System, and engagement with payers for PDN and NSRBP.
Overall, Nevro anticipates gradual growth throughout 2023, with minimal impact expected from new competitors like Medtronic and Abbott.

Nevro surpasses Q1 expectations, poised for sustained growth ahead

Nevro's Q1 performance exceeded expectations, showcasing strong growth and positive market reception. With a focus on disruptive technologies, new product launches, and market expansion, the company is well-positioned for continued success amidst optimistic market dynamics.

Nevro reports solid Q2 results, focuses on market growth strategies

Nevro's Q2 2023 performance showed revenue growth and focus on market penetration, with challenges in sales force turnover and competition.
Strengths lie in expanded PDN coverage, clinical data emphasis, and reimbursement wins, while opportunities include market growth and enhanced sales productivity.
Addressing challenges through realignment efforts and compensation plans, Nevro aims to leverage market opportunities and drive profitability in the coming months.
Guidance considers turnover impact, territory rebuilding, and sustained business through therapy consultants, positioning Nevro for future growth and success.

Nevro excels in Q3 earnings, eyes growth through innovative therapies

Nevro's Q3 performance reflects strong revenue growth and success in the PDN market, driven by innovative SCS therapy solutions.
The company's strategic focus on commercial execution, market penetration, and operational efficiencies positions them for future success.
Challenges include increasing market penetration, balancing margin expansion with operational efficiency, and careful consideration of acquisitions.
Opportunities lie in leveraging low market penetration, enhancing customer engagement, and collaborating with key experts for continued growth.

Nevro reports solid Q4 revenue growth, eyes market expansion

Nevro's Q4 2023 performance reflects revenue growth driven by PDN sales, with positive EBITDA and strategic acquisitions enhancing market positioning.
While challenges in operational profitability persist, Nevro's focus on market penetration, physician engagement, and salesforce effectiveness present growth opportunities.
Analyst inquiries into market dynamics, competition, and product differentiation underscore the need for Nevro to navigate operational challenges and capitalize on growth prospects.

Nevro surpasses Q1 expectations, eyes market expansion and margin growth

Nevro's Q1 2024 performance exceeded guidance, driven by HFX iQ and increased replacement device candidates, with restructuring efforts to generate savings in 2024.
Strengths include FDA clearance for Nevro1 in SI joint fusion, Android compatibility for HFX iQ, and focus on expanding market penetration.
Challenges include U.S. trials decline, COGS pressure anticipated, and ensuring sales reps are up to speed, while opportunities lie in expanding margins and market penetration.
Overall, Nevro's strategic focus on SI joint fusion products and margin expansion positions them for growth in 2025 and beyond.

Nevro faces revenue decline but pursues strategic growth initiatives

Nevro's Q2 performance reflects revenue challenges but maintains a positive adjusted EBITDA amidst market pressures.
The company's strategic focus on diversification, commercial execution, and exploring strategic options highlights a proactive approach to driving growth.
With a strong cash position and ongoing efforts to navigate challenges and capitalize on opportunities, Nevro is poised for future success.

Nevro reports revenue decline in Q3 but advances AI therapy

Nevro faced revenue decline in Q3 2024 but maintained stability and improved cash position.
Strategic actions to enhance commercial execution and product innovation show promise for future growth.
Challenges in revenue and profitability persist, but opportunities in therapy expansion and market diversification exist.
Continued focus on cost management and strategic exploration to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., April 13, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D.

Nevro to Present at BofA Securities 2021 Virtual Health Care Conference

REDWOOD CITY, Calif., April 7, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021.

Nevro to Report First Quarter 2021 Financial Results

Painful diabetic neuropathy [PDN] is a condition that affects ~30% of diabetics; there are various treatments but no cure.

Nevro: Harvesting An Epic Growth Opportunity

REDWOOD CITY, Calif., April 5, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that results of its SENZA-PDN randomized clinical trial (RCT) were published online in JAMA Neurology.

Nevro Announces Publication Of Landmark SENZA-PDN Clinical Trial Results In JAMA Neurology

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

Why Is Nevro (NVRO) Down 16% Since Last Earnings Report?

Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.

Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss

Nevro Corp (NVRO) CEO Keith Grossman on Q4 2020 Results - Earnings Call Transcript

Shares of Nevro (NYSE:NVRO) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 52.27% year over year to ($0.21), which beat the estimate of ($0.33).

Recap: Nevro Q4 Earnings

REDWOOD CITY, Calif., Feb. 24, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full year ended December...

Nevro Reports Fourth Quarter and Full Year 2020 Financial Results

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

REDWOOD CITY, Calif., Jan. 27, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter...

Nevro to Report Fourth Quarter and Full-Year 2020 Financial Results

REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the results from data presentations at NANS supporting the use of HF10®...

Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro's HF10® Therapy

BJ`s Wholesale Club Holdings Inc

Fate Therapeutics

Golar LNG

Chart Industries

Health Catalyst Inc

II-VI Incorporated

LivePerson

PDC Energy Inc

Papa John's

QTS Realty Trust

If you desire growth, then your sights should be set on small-cap stocks. These 11 have attracted the gaze of dozens of Wall Street's best minds.

11 Small-Cap Stocks the Analysts Love for 2021

Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.

Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues

Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.

Nevro's (NVRO) FDA Submission to Treat Patients With PDN

REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company has submitted a pre-market approval supplement to the...

Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy

REDWOOD CITY, Calif., Dec. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it will host and webcast a virtual investor briefing at the 2021 North...

Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference

Nevro has been prospering in its chosen specialty of opioid-free pain relief. Nevro's Omnia launch has been dampened by the pandemic; expect good things as the pandemic moves to the rear.

Nevro: More Opioid-Free Pain Relief

REDWOOD CITY, Calif., Dec. 15, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present...

Nevro to Present at 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

Boston Scientific

MARLBOROUGH, Mass., Dec. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO) patent infringement case against Boston Scientific in the United States District Court for the...

Boston Scientific Announces Stipulation Of Dismissal Of Nevro Corporation's Patent Infringement Case In California

REDWOOD CITY, Calif., Dec. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that, in its patent litigation against Boston Scientific, the parties...

Nevro Announces Agreement to Conclude Its Patent Lawsuit in the Northern District of California Against Boston Scientific

Why Is Nevro (NVRO) Up 1.7% Since Last Earnings Report?

REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor...

Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

REDWOOD CITY, Calif., Nov. 24, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President will...

­Nevro to Participate in Citi Bank Head Shoulders Knees and Toes Conference Call Series on November 30th

REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced today that both data abstracts for Painful Diabetic Neuropathy (PDN) and...

Nevro Announces Abstract Presentations for PDN and NSRBP Trials Have Been Accepted for the Late Breaking Trials Plenary Session at NANS 2021 Conference

News for Nevro Stock (NVRO)